Unknown

Dataset Information

0

Long-Term Outcomes of Group B Eyes in Patients with Retinoblastoma Treated with Short-Course Chemoreduction: Experience from Children's Hospital Los Angeles/University of Southern California.


ABSTRACT:

Background/aims

Chemoreduction protocols for retinoblastoma vary widely across institutions. Herein, we compare a 3- versus 6-cycle chemotherapy approach for group B retinoblastoma.

Methods

A nonrandomized, retrospective review of patients diagnosed with group B retinoblastoma from 1991-2011 at Children's Hospital Los Angeles was performed. A total of 72 eyes of 63 patients were analyzed. Mean follow-up time was 82 months (range 6-272 months). Main outcome measures were globe salvage and need for external beam radiation.

Results

Forty-six patients (55 eyes) were treated upfront with 3 cycles of carboplatin, etoposide, and vincristine; 17 patients (17 eyes) received 6 cycles. Thirty-seven eyes (67%) in the 3-cycle group were cured with initial chemoreduction alone. An additional 10 eyes with persistent or recurrent tumors were rescued with 3 more cycles for a total salvage rate of 85% (47/55 eyes). In the 6-cycle group, 16 of 17 eyes (94%) avoided radiation and enucleation.

Conclusion

The initial recurrence rate was higher for the 3-cycle group (p = 0.03). However, eyes failing short-course chemoreduction were rescued with 3 additional cycles and achieved a similar overall event-free survival rate (p = 0.16). In our cohort, this short-course approach spared 63% (29/46) of patients with group B retinoblastoma the extra 3 cycles of systemic chemotherapy.

SUBMITTER: Zhu D 

PROVIDER: S-EPMC4847672 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Outcomes of Group B Eyes in Patients with Retinoblastoma Treated with Short-Course Chemoreduction: Experience from Children's Hospital Los Angeles/University of Southern California.

Zhu Dagny D   Berry Jesse L JL   Ediriwickrema Lilangi L   Wong Kenneth K   Lee Thomas C TC   Murphree A Linn AL   Kim Jonathan W JW   Jubran Rima R  

Ocular oncology and pathology 20151105 2


<h4>Background/aims</h4>Chemoreduction protocols for retinoblastoma vary widely across institutions. Herein, we compare a 3- versus 6-cycle chemotherapy approach for group B retinoblastoma.<h4>Methods</h4>A nonrandomized, retrospective review of patients diagnosed with group B retinoblastoma from 1991-2011 at Children's Hospital Los Angeles was performed. A total of 72 eyes of 63 patients were analyzed. Mean follow-up time was 82 months (range 6-272 months). Main outcome measures were globe salv  ...[more]

Similar Datasets

| S-EPMC8647877 | biostudies-literature
| S-EPMC2430119 | biostudies-other
| EGAO00000000922 | EGA
| S-EPMC3311208 | biostudies-literature
| S-EPMC6460273 | biostudies-literature
| S-EPMC3309692 | biostudies-literature
| S-EPMC3621187 | biostudies-literature
| S-EPMC8423334 | biostudies-literature
| S-EPMC8586628 | biostudies-literature
| S-EPMC2744237 | biostudies-literature